Being overweight as a young child could double risk of adult obesity, research shows
Being overweight as a young child could double the risk of being obese in adulthood, according to research.
Academics from the Netherlands said the body mass index (BMI) of six-year-olds is the most reliable predictor of obesity in adulthood and the first five years are critical in preventing weight gain.
The study tracked the BMI of thousands of children in the Netherlands at age two, six, 10, 14 and 18, and found that every one-unit increase in BMI at age six more than doubled a child's odds of being overweight or obese at 18.
The research, presented at the European Congress on Obesity in Málaga, also found overweight children who reached a healthier weight before they turned six were no longer at higher risk of being overweight or obese in their late teens. But if they lost weight after that age, they still had an elevated chance.
Of the 3,528 young people, 32.3% were considered overweight or obese at age two, with 22.3% at age six, 24.7% at age 10 and 20.6% at age 14.
Many of these children were still classed as overweight or obese at 18.
Jasmin de Groot, of Erasmus University Medical Center in Rotterdam, said: 'We need to understand how children grow and develop if we are to help future generations grow up healthier and give every child a chance at a happy, healthy life.'
She added: 'The first five years of a child's life provide a fantastic opportunity to intervene and prevent them experiencing overweight and obesity in the years to come.'
Related: Children as young as two treated for obesity-related illness in England
Separate research by the University of Bristol presented at the congress found the number of overweight teenagers in England has increased by 50%, from 22% in 2008-2010 to 33% in 2021-2023.
Lead researcher Dr Dinesh Giri, consultant paediatric endocrinologist at Bristol Royal Hospital for Children, said: 'Over the past 15 years, obesity in adolescents has risen significantly due to a combination of increased consumption of ultra-processed foods, sedentary lifestyles driven by excessive screen time, inadequate sleep, and rising mental health challenges.
'Additionally, reduced opportunities for physical activity and socioeconomic disparities have further contributed to an environment that promotes unhealthy lifestyles.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 hours ago
- Medscape
Fast Five Quiz: Ovarian Cancer Overview
Ovarian cancer poses a significant threat to women's health, often developing quietly and without early symptoms. It is commonly discovered after progression. This late detection, along with resistance to treatment and frequent relapse, contributes to poor outcomes. Although medical and surgical interventions have evolved, survival rates remain low. These challenges highlight the critical importance of early detection methods, precise diagnostic technologies, and individualized care coordinated across medical specialties. How much do you know about ovarian cancer? Test your knowledge with this quick quiz. High-grade serous carcinoma is by far the most prevalent, representing approximately 70%-80% of epithelial ovarian cancer cases. In contrast, the low-grade form of serous carcinoma is much less common (< 5%). Endometrioid and clear cell subtypes are each responsible for about 10% of cases and have known associations with endometriosis. Mucinous carcinomas are uncommon, comprising a small fraction (around 3%) of epithelial ovarian cancers. Learn more about ovarian cancer. According to the National Institute for Health and Care Excellence guidelines, for patients with inherited mutations linked to a higher chance of developing ovarian cancer (eg, alterations in BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 ), the most effective preventive surgical procedure is the bilateral salpingo-oophorectomy (which is the removal of both fallopian tubes and ovaries). This intervention has been proven to greatly reduce ovarian cancer risk and enhance long-term survival among these high-risk groups. However, when performed in premenopausal women, it induces menopause. Removing one ovary (unilateral oophorectomy) or the uterus (total hysterectomy) does not offer adequate protection against ovarian cancer. Procedures like cervical conization are unrelated to ovarian cancer and are used to manage cervical abnormalities. Learn more about salpingo-oophorectomy. HRT is typically recommended for women who undergo bilateral salpingo-oophorectomy before reaching the natural age of menopause and have not had breast cancer. This type of surgery causes a sudden and early drop in estrogen levels, which can result in bothersome symptoms and increase the risk for long-term health issues such as bone loss or cardiovascular problems. HRT helps ease these effects and maintain health until the typical menopausal age. In contrast, women older than age 50 years are often already in or near menopause, and HRT is not routinely needed unless specific symptoms arise. Patients who have a history of breast cancer must be assessed on a case-by-case basis because HRT might not be safe. Women with a uterus should be offered combined HRT, whereas women without a uterus should be offered estrogen-only HRT. Additionally, women who have not had their ovaries removed do not experience the abrupt hormonal shift that warrants preventive HRT. Learn more about HRT. Individuals who carry a BRCA1 mutation face a significantly elevated risk of developing ovarian cancer, often at a younger age than those with other hereditary mutations. If a woman with a BRCA1 mutation decides not to undergo surgery to remove her ovaries and fallopian tubes, monitoring for early signs of cancer should begin after age 35 years. This timing aligns with evidence suggesting that BRCA1 -related ovarian cancers tend to occur earlier than those linked to BRCA2 or other genetic variants. Initiating surveillance at age 30 years is generally premature and not part of standard recommendations. For BRCA2 carriers, screening is usually deferred until after age 40 years, whereas those with alterations in genes like RAD51C, RAD51D, BRIP1 , or PALB2 typically begin surveillance after age 45 years. Individuals with Lynch syndrome-related mutations (eg, MLH1, MSH2, MSH6 ) are also advised to start at age 35 years if surgery is postponed. Learn more about breast cancer risk factors. Although mucinous tumors can arise directly from the ovary, many are actually secondary cancers that have spread from other organs, most notably the gastrointestinal system, including the colon and appendix. Distinguishing between primary and metastatic mucinous tumors is crucial for proper diagnosis and management. High-grade serous cancers more commonly begin in the epithelium of the fallopian tubes rather than the ovaries. On the other hand, low-grade serous carcinomas are thought to originate in the ovary and are typically diagnosed in younger females, with outcomes generally more favorable than their high-grade counterparts. Germ cell tumors and sex cord-stromal tumors are far more frequent in adolescents and young adults, with most cases occurring before age 30 years and not in women older than 45. Learn more about endometrioid carcinoma.
Bloomberg
6 hours ago
- Bloomberg
Lilly's Experimental Obesity Drug Shows Promise in Early Study
By An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in the obesity market. The drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months, according to an abstract posted Friday ahead of the American Diabetes Association conference in Chicago. The drug is moving to the next stage of development and researchers will present details on dosing and safety at the conference next week.
Forbes
7 hours ago
- Forbes
Colon Cancer Cases Are Rising. Here's How To Get Screened.
Photo of person getting colon cancer screening Colon cancer is a leading cause of cancer-related deaths. It typically begins as a small growth of tissue called a polyp in the lining of the colon or rectum. While not all polyps become cancerous, most colon cancers start as polyps, making early detection and removal critical. Fortunately, colon cancer is highly preventable and survivable. Regular screening plays a key role in identifying and removing precancerous polyps and early-stage cancers, when treatment is most effective. In fact, 9 out of 10 people survive when colon cancer is found early. Without screening, undetected cancers can progress to advanced stages, such as Stage III and IV, which are associated with poorer outcomes. Colorectal cancer is projected to claim 53,000 lives in 2025. Understanding your colon cancer screening options will allow you to make informed choices alongside your clinician. The American Cancer Society now recommends that individuals at average risk begin regular colon cancer screening at age 45, a shift from the previous benchmark of 50. The lowered screening age reflects rising rates of colon cancer in younger adults and historically low screening compliance for older adults. You may need to start earlier than 45 if you have: As an example, if your sibling was diagnosed with Stage 1 colon cancer at age 40, you wouldn't wait until 45 for your first colonoscopy. Instead, you'd start 10 years before their diagnosis—at age 30. Given how risk factors change one's initial screening age it is of critical importance for individuals to know their personal and family history when speaking with their clinician about initial screening. Reminder on to do list to schedule a colonoscopy 1. Colonoscopy What it is: A procedure that uses a flexible tube with a camera to examine the entire colon. If polyps are found, they can be removed during the procedure. 'A colonoscopy is the gold standard and most preferred method because we can examine the entire colon, locate where the early growths (polyps) are, and remove them on the spot. This is what makes a colonoscopy a cancer prevention procedure," says Dr. Austin Chiang, Gastroenterologist and author of Gut: An Owner's Guide. Other details: This procedure requires patients to undergo preparation (e.g. dietary modifications and laxatives) beforehand to clear the colon so that there is adequate visualization. Since it is performed under sedation most people experience little to no discomfort and have no memory of the exam. The entire process usually takes less than an hour. 2. Flexible Sigmoidoscopy What it is: A flexible sigmoidoscopy examines only part of the colon, called the sigmoid colon, where colorectal cancer is commonly found. 'Some prefer this method because it doesn't require drinking a full bowel prep, but the tradeoff is that most of the colon is left unexamined," says Chiang. Other details: Flexible sigmoidoscopy often uses lighter sedation or none at all. Some patients may experience mild cramping during the approximately 20-minute procedure. While less comprehensive than a full colonoscopy, it can be a more convenient option for some. 3. CT Colonography What it is: A CT scan that produces 3D images of the colon and rectum to identify abnormalities. However, 'if any abnormalities are found, a traditional colonoscopy is still required for further evaluation or removal, ' says Chiang. Other details: It exposes patients to a low dose of radiation and is best at detecting larger polyps (>1cm). Thus smaller polyps may go undetected. 4. Capsule Endoscopy (e.g. Pill Endoscopy) Camera capsule for intestinal examination What it is: A swallowable capsule with a tiny camera that takes thousands of pictures as it travels through the digestive tract. 'Capsule endoscopy can be used to visualize the colon only after incomplete or inadequate colonoscopy. Like other non-invasive tests, including CT colonography, no intervention can be performed during the test,' says Chiang. Other details: Capsule endoscopy is painless and does not require sedation, but preparation is similar to that for a colonoscopy. The images are transported to an external wearable device and the capsule does not need to be returned. This test's accuracy can vary based on preparation of bowel. It cannot remove polyps. 5. Fecal Immunochemical Test (FIT) What it is: A stool test that detects hidden (occult) blood in the stool, which may signal cancer. 'A FIT test is done annually, and is designed to detect hidden blood coming from the colon. It is a noninvasive colorectal cancer detection test, designed to detect colorectal cancer," says Dr. Sophie Balzora, Gastroenterologist at NYU. Other details: FIT does not require any bowel preparation or dietary restrictions, making it a more convenient option. However, it cannot detect precancerous polyps and must be completed annually to remain effective. 6. Guaiac-based Fecal Occult Blood Test What it is: Similar to FIT but uses a different chemical method to detect blood in the stool. 'This has essentially fallen out of favor. There are better screening detection tests available for average-risk individuals," says Balzora. Other details: This test may require dietary changes before stool sample collection. It is recommended annually but is less accurate and largely outdated. 7. Stool DNA Test (e.g. Cologuard) What it is: Stool DNA test combines FIT with a DNA test to detect cancer-related DNA mutations in stool. 'It is done every 3 years assuming a negative test. It, too, is designed to detect colorectal cancer, and not the precancerous growths, or polyps, ' says Balzora. Other details: It requires no dietary restrictions ahead of giving a stool sample. However, positive results necessitate follow-up with a colonoscopy. Colon cancer screening is not a one time event. It needs to be repeated to monitor for interval change in the colon. However, the frequency of screening is variable. 'If someone has many precancerous polyps, even one large polyp (over 1 cm—about the size of a pea), or polyps with certain microscopic features, they are recommended to come in sooner for their next colonoscopy than someone at average risk or with no prior polyps,' says Balzora. Regular screening for colon cancer is a powerful tool in reducing the incidence and mortality associated with the disease. While the gold standard test is a colonoscopy, the right test for you depends on your risk level, personal preferences, and access to testing. Speak with your healthcare provider to determine the most appropriate option and timing. The most important point is to not delay screening.
